Related Experiment Videos
Incomplete tolerance to the tumour-associated antigen MDM2
Francisco Ramírez1, Yasmeen Ghani, Hans Stauss
1Tumour Immunology Laboratory, Department of Immunology, Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK. f.ramirez-jimenez@imperial.ac.uk
International Immunology
|January 22, 2004
Summary
Targeting the tumor antigen MDM2 for immunotherapy is complex. While one MDM2 peptide induced high-avidity cytotoxic T lymphocytes (CTLs), targeting multiple MDM2 epitopes may be necessary for effective tumor vaccination.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- MDM2 is a tumor-associated antigen overexpressed in many cancers.
- Understanding immunological tolerance to MDM2 is crucial for developing effective cancer immunotherapies.
Purpose of the Study:
- To investigate the in vivo immunogenicity of two murine MDM2 epitopes (pMDM100 and pMDM441) with differing MHC class I affinities.
- To explore the potential of MDM2 targeting for tumor immunotherapy.
Main Methods:
- Immunization of mice with individual or combined MDM2 peptides (pMDM100, pMDM441).
- Assessment of cytotoxic T lymphocyte (CTL) generation and tumor cell killing.
- Evaluation of tumor protection against challenge.
Main Results:
- Immunization with pMDM100 surprisingly generated high-avidity CTLs against MDM2-expressing tumor cells.
- CTL responses were limited and diminished with prolonged in vitro stimulation.
- Individual peptide immunization did not confer tumor protection, but combined immunization offered partial protection.
Conclusions:
- High-avidity CTLs can be generated against widely expressed self-antigens like MDM2.
- Targeting multiple MDM2 epitopes may be essential for successful tumor vaccination strategies.
- Further research is needed to overcome limitations in sustaining anti-tumor immune responses.